Welcome to the SWYAPC website
The information on these pages is intended as a guide only. Whilst we endeavour to keep such information as up to date as possible, we make no claim as to its total accuracy or completeness. Information is liable to change, and such changes may not be mirrored in this site. We do not accept liability for any loss or damage resulting from use of this site or reliance on its content. External links lead to sites and pages over which we have no control, and which we cannot verify for accuracy or content. The inclusion of a link on this website should not be taken as an endorsement of the linked website, nor of the accuracy or quality of the information on such sites.
Updates following the January 2019 Area Prescribing Committee Meeting
Red, Black, Green Classifications, Black not yet classified:
Dupilumab for atopic dermatitis in adults (TA534)
Brodalumab for moderate to severe plaque psoriasis in adults (TA511)
Guselkumab for moderate to severe plaque psoriasis in adults (TA521)
Tofacitinib – new indication for the treatment of active psoriatic arthritis in adults (TA543)
Sarilumab for moderate to severe active rheumatoid arthritis in adults (TA485)
Gemtuzumab ozogamin for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia (APL).(TA545)
Green Specialist Initiation
Metolozone for heart failure
Levetiracetam injection for use in palliative care
Nefopam – Black for new patients
Black not yet classified (New classification)
Xonvea® – Black for nausea and vomiting in pregnancy.
The drugs and devices in this category have reached the market but have not yet been classified by the NHS locally.
Primary Care Antimicrobial Guidelines
On 16 January 2019 the South West Yorkshire Area Prescribing Committee approved local use of the new NICE/PHE managing common infections guidance.
This supersedes our local primary care guideline. As NICE/PHE have not completed all sections yet, we will continue to use local guidelines for those sections.
NICE/PHE – introduction to guidelines
NICE/PHE table – managing common infections (whole guideline)
Commissioning Position – Flash Glucose Monitoring Systems – November 2018
The expected cost of the Flash Glucose Monitoring Systems to the NHS is over £900 per patient per year of continuous use compared with £360 – £650 per patient per year for finger pricking (based on testing 4-8 times per day). Therefore, it is currently unaffordable and unsustainable to make it available for all people with diabetes.
Bradford City and Districts CCGs, Calderdale CCG, Greater Huddersfield CCG, North Kirklees CCG and Wakefield CCG and local diabetes specialists have agreed which groups of patients would gain most health benefit from using Flash Glucose Monitoring Systems, whilst keeping it affordable for the NHS.
Flash Glucose Monitoring Systems are routinely commissioned for adult and child patients with type 1 diabetes mellitus in certain circumstances. These criteria can be found in the Commissioning Statement Tracker on the Commissioning Statements page. Requests for other patients, who exhibit exceptionality, will need to go through the IFR process. GPs should NOT initiate any prescriptions for Flash Glucose Monitoring Systems.
Valproate Pregnancy Prevention Programme
Skin preparations (emollients)
West Yorkshire Fire & Rescue Service has produced YouTube Videos for the public and patients and one for healthcare professionals warning that skin preparations can increase the risk of a fire developing. The YouTube videos have been added to the following sections of the website for information and discussion: Medicines Alerts and Safety Issues, Patient Information and Care Homes. There is also information on the Fire Service’s website. The MHRA has issued a press release.
The new plan includes a strong focus on infection prevention and control and a target to reduce UK antimicrobial use in humans by 15% by 2024.